Biolidics expects 'strong interest' in share placement

Singapore

CANCER diagnostics company Biolidics is expecting "strong interest" for its share placement that could raise some S$3.1 million to fuel its business expansion and pursue new growth opportunities.

"While the current market conditions are choppy, we are encouraged that Biolidics' share placement exercise has attracted strong interest and we look forward to accelerating our plans to enable greater market outreach and accessibility to our pipe-line of diagnostic solutions," Biolidics' non-executive and non-independent chairman Jeremy Yee told BT on Monday.